Abcam, ab259133, Human SLC39A9 (ZIP-9) knockout HeLa cell lysate

Size: 1Kit
SLC39A9 KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon1 and 5 bp deletion in exon1.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon1 and 5 bp deletion in exon1.,
Disease:Adenocarcinoma

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-SLC39A9, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
ZIP-9 also known as SLC39A9 is a member of the zinc transporter family that plays an important role in regulating zinc homeostasis. It functions by facilitating the influx of zinc from extracellular space into the cytoplasm. ZIP-9 with a molecular mass of approximately 35 kDa is expressed in various tissues including the liver kidney and reproductive organs. It possesses a characteristic structure with eight transmembrane domains and is localized primarily in the plasma membrane and the endoplasmic reticulum.
Biological function summary
ZIP-9 acts as a membrane androgen receptor and is involved in non-genomic androgen signaling. It does not typically form part of a larger complex but its activity greatly influences cellular zinc levels and hormone signaling pathways. ZIP-9 triggers rapid signaling events upon androgen binding which may affect multiple cellular processes including apoptosis proliferation and differentiation indicating its role in cellular response to hormonal and nutritional changes.
Pathways
Zinc is a central element in cellular signaling processes which involve ZIP-9 particularly in the MAPK and PI3K-Akt signaling pathways. ZIP-9's role in zinc transport affects these pathways by regulating intracellular zinc concentrations which in turn can influence downstream signaling events. ZIP-9 interactions with other proteins such as ZIP4 in the zinc transporter family impact zinc-mediated signaling dynamics and cellular homeostasis.
Abnormal ZIP-9 function has been associated with prostate cancer and polycystic ovary syndrome (PCOS). In prostate cancer ZIP-9's role in androgen signaling enhances tumor cell growth and proliferation linking it to androgen receptor pathways. Likewise in PCOS disturbances in zinc metabolism through ZIP-9 can contribute to the hormonal imbalances observed in this disorder. Studying ZIP-9 interactions particularly with androgen receptors may provide insights into therapeutic strategies for these conditions.